Yposkesi chairman to speak on ‘Manufacturing and the CDMO Perspective’ at Cell and Gene Meeting

NewsGuard 100/100 Score

Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announces that its chairman Frederic Revah Ph.D. will participate as a panelist on the topic of ‘Manufacturing and the CDMO Perspective’. The event is hosted by the Cell and Gene Meeting on the Mediterranean taking place in Barcelona, Spain, April 23 – 25, 2019.

While viral vector manufacturing is expected to grow at a CAGR of 20% over the next few years to reach $1.4 billion by 2026, it is creating a bottleneck for developers of gene therapies seeking to advance clinical trials and commercialize new therapeutic drugs.

Moderated by Thomas Fellner, Ph.D., global head of business development and account management, Cell and Gene Technologies at Lonza, Frederic Revah will join fellow speakers, Joseph Tarnowski, Ph.D., SVP, cell and gene therapy platforms, medicinal science and technology, R&D at GSK and Kim Warren, head of operations of Avrobio and Catherine Cancian, VP, pharmaceutical operations at GenSight Biologics.

The Cell & Gene Meeting on the Mediterranean is a two-day conference bringing together leading cell, gene therapy and tissue engineering companies from around the world. It covers a wide range of key topics from market access and regulatory issues to manufacturing and financing the sector.

Event: Cell and Gene Meeting on the Mediterranean
Topic: Manufacturing and the CDMO Perspective
Date: Tuesday April 23, 2019
Time: 4:30 pm - 5:30 pm

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patients